Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression
about
Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor ImmunityEvaluation of current cancer immunotherapy: hemato-oncologyToward development and production of human T cells in swine for potential use in adoptive T cell immunotherapy.Histone acetylation at the Ifng promoter in tolerized CD4 cells is associated with increased IFN-gamma expression during subsequent immunization to the same antigenInflammation programs self-reactive CD8+ T cells to acquire T-box-mediated effector function but does not prevent deletional toleranceBispecific antibodies engage T cells for antitumor immunotherapy.Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure.Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression.CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.Extracellular NM23 Signaling in Breast Cancer: Incommodus Verum.Epigenetic quantification of tumor-infiltrating T-lymphocytes.Expression of tumour-specific antigens underlies cancer immunoeditingAmplification of tumor-specific regulatory T cells following therapeutic cancer vaccinesEarly manifestations of NNK-induced lung cancer: role of lung immunity in tumor susceptibility.Tumor-infiltrating T lymphocytes: friends or foes?Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells.Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrenceThe tumor-draining lymph node as an immune-privileged site.The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cellsCancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.Tumor immunoediting and immunosculpting pathways to cancer progression.Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses.Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics.Improving T cell responses to modified peptides in tumor vaccinesBetting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation.The interplay between HPV and host immunity in head and neck squamous cell carcinoma.Cellular and molecular mechanisms in cancer immune escape: a comprehensive review.Immunotherapeutic approaches for cancer therapy: An updated review.Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity.Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer.
P2860
Q26782201-DEC17323-B5A7-4F8E-97B5-DD676DC223AEQ27006179-6B814626-6328-420F-A589-23ECCC9D0062Q33606412-04FBA014-B4E7-4A7F-9993-5A2C2D5C4351Q33791226-6F7E94FB-C05A-45D9-BFD3-4E471874272EQ34066709-9D6309C7-3D6E-426C-A469-B4F805D04248Q34174334-01A00ACB-9D43-4711-92CA-5CF20E6381ACQ34335039-5250CA83-F5CE-4170-A520-CF5F49FF165FQ34755544-8BA83238-A862-4103-8B8C-C51507D50358Q35228053-019654A9-4608-40B5-AC35-0F738025FFFEQ35546643-6AC08FFA-124A-420A-B436-BD5294C6875AQ35754836-0A9D1B79-DDE5-4E31-AC7F-59CF1CC2B8D0Q35785378-80A2CE3F-E619-4E32-B17F-9760B0542030Q35849310-16DF7375-8897-4B6C-B5A9-97B31DA6F323Q35855247-A36F2E4E-1D8F-4662-9E77-2E18E1053600Q36381918-B9B27015-7C18-47B5-93F1-F84BE811A470Q36482614-B4F46E6B-62E5-4404-9F5B-DA7D496701F9Q36569004-2C97A01D-D777-4330-B95D-600335CA1BB9Q36570359-C7E48052-6669-4EE2-A26F-25F7DC9745C5Q36593753-34BD2620-9FA1-42EB-840F-85726ED10C04Q36649570-A43D91CA-4584-4564-8A4E-841B6E3DB015Q36690273-8E83BA40-E0CF-4851-B7A6-72A4EDAF0808Q36891034-E2359686-70F4-4723-9A00-2CFD346EC908Q36896195-C75525EE-8045-4EDA-BD29-C6FFDE7FB9C6Q36983599-34C53C96-E755-4C65-A3CE-3123A1D4178BQ37306957-E50D4BB5-2159-40F9-8658-0042FF6CA147Q37387518-00486814-6D19-4A9F-B0B0-BE70AB342412Q37634253-B227A34B-F61B-48D0-978B-E4605E2404ECQ38088635-5FA6F676-84FA-427A-97AB-288C1B01A0DEQ38126455-DEF7B045-F0AA-4555-8E87-1B9A90EDF15BQ38170150-504F5DC5-AB6E-452A-AF9A-B9010B5DCCFCQ38388102-8439AB67-5FF2-4EDC-973A-9E084E5A7BC0Q38779877-445773E8-D071-4F2F-81A9-46D070CC9AA0Q38810148-EBA36509-4D93-4AFA-87F9-60042AC7EF14Q39013616-0A8123F8-AD83-472D-A383-81A519C45051Q39093893-BF7320B1-6CF2-418C-A198-CD191368DCBCQ40327982-5A284CB9-5947-4634-8802-1ACD1D3A0F3FQ47160687-8C2C0F00-A793-4852-B4E6-26F9A699E1E6
P2860
Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Reciprocal changes in tumor an ...... ction during tumor progression
@ast
Reciprocal changes in tumor an ...... ction during tumor progression
@en
type
label
Reciprocal changes in tumor an ...... ction during tumor progression
@ast
Reciprocal changes in tumor an ...... ction during tumor progression
@en
prefLabel
Reciprocal changes in tumor an ...... ction during tumor progression
@ast
Reciprocal changes in tumor an ...... ction during tumor progression
@en
P2093
P2860
P356
P1476
Reciprocal changes in tumor an ...... ction during tumor progression
@en
P2093
Aimee L Marson
Hyam I Levitsky
John D McCadden
Zhengbin Lu
P2860
P304
P356
10.1084/JEM.20041240
P407
P577
2004-12-13T00:00:00Z